Cat. No.: DAA-001322
Product Information | |
---|---|
Product Name | Porcine Osteoprotegerin ELISA Kit (OPG) |
Species | Pig |
Description | Porcine Osteoprotegerin ELISA Kit (OPG) is an in-vitro enzyme-linked immunosorbent assay for the quantitative measurement of porcine Osteoprotegerin in serum, plasma and cell culture supernatants. This assay employs an antibody specific for porcine Osteoprotegerin coated on a 96-well plate. Standards and samples are pipetted into the wells and Osteoprotegerin present in a sample is bound to the wells by the immobilized antibody. The wells are washed, and biotinylated anti-porcine Osteoprotegerin antibody is added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin is pipetted to the wells. The wells are again washed, a TMB substrate solution is added to the wells and color develops in proportion to the amount of Osteoprotegerin bound. |
Sample Types | Cell Culture Supernatant, Serum, Plasma |
Detection Range | 0.123 ng/mL - 30 ng/mL |
Sensitivity | 0.12 ng/mL |
Target Information | |
---|---|
Target Name | TNFRSF11B |
UniProt No. | O00300 |
Gene ID | 4982 |
Target Description | Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis. |
Alternative Names | MGC29565; OCIF; OPG; Osteoclastogenesis inhibitory factor; Osteoprotegerin; PDB5; TNF receptor superfamily member 11b; TNFRSF 11B; TNFRSF11B; TR 1; TR1; TR11B_HUMAN; Tumor necrosis factor receptor superfamily member 11B |
Shipping & Storage | |
---|---|
Sipping | Shipping on dry ice. |
Storage | Store at -20°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.